Shizuo Yamada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shizuo Yamada has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
Yoshihiko Ito
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
22 shared publicationsSatomi Onoue
Laboratory of Biopharmacy, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
8 shared publicationsKazumasa Shinozuka
Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan
7 shared publicationsShiori Kuraoka
Department of Pharmacokinetics and Pharmacodynamics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
7 shared publicationsAyaka Osano
Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka
6 shared publications- Satomi Onoue
Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
6 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by MDPI AG in Future Pharmacology
- Vol. 6 (1) , 7
Off-Target Effects of Mirabegron on Muscarinic Receptors
Older adults with multiple diseases are likely to be prescribed multiple medications including anticholinergic agents, which are frequently prescribed to manage conditions such as overactive bladder and chronic obstructive pulmonary disease and Parkinson’s disease. Overactive bladder (OAB) has been the subject of increased disease awareness and is a common and significant cause of reduced quality of life, particularly in the elderly. The selective β3 adrenoceptor agonist, mirabegron was developed for the pharmacological treatment of OAB. Mirabegron has been shown to exert off-target effects on various functional proteins such as muscarinic receptors in rat tissues. This agent may relax the detrusor muscle by activating β3 adrenoceptors and also antagonizing muscarinic receptors. Mirabegron and antimuscarinics exerted additive effects on muscarinic receptor binding and relaxant responses of cholinergic contractions of the detrusor muscle. Mirabegron excreted in human urine appears to directly attenuate muscarinic receptor-mediated functions in the bladder. Combination therapy of mirabegron and solifenacin in patients with OAB may enhance not only their therapeutic effects on OAB, but also increase the risk of anticholinergic adverse effects. Therefore, the safety of concomitant use of mirabegron and other drugs such as antimuscarinics for elderly patients needs to be carefully considered.
- 30 January 2026
- Published by MDPI AG in Future Pharmacology
- Vol. 6 (1) , 7
Open AccessOff-Target Effects of Mirabegron on Muscarinic Receptors
Older adults with multiple diseases are likely to be prescribed multiple medications including anticholinergic agents, which are frequently prescribed to manage conditions such as overactive bladder and chronic obstructive pulmonary disease and Parkinson’s disease. Overactive bladder (OAB) has been the subject of increased disease awareness and is a common and significant cause of reduced quality of life, particularly in the elderly. The selective β3 adrenoceptor agonist, mirabegron was developed for the pharmacological treatment of OAB. Mirabegron has been shown to exert off-target effects on various functional proteins such as muscarinic receptors in rat tissues. This agent may relax the detrusor muscle by activating β3 adrenoceptors and also antagonizing muscarinic receptors. Mirabegron and antimuscarinics exerted additive effects on muscarinic receptor binding and relaxant responses of cholinergic contractions of the detrusor muscle. Mirabegron excreted in human urine appears to directly attenuate muscarinic receptor-mediated functions in the bladder. Combination therapy of mirabegron and solifenacin in patients with OAB may enhance not only their therapeutic effects on OAB, but also increase the risk of anticholinergic adverse effects. Therefore, the safety of concomitant use of mirabegron and other drugs such as antimuscarinics for elderly patients needs to be carefully considered.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 907
Shedding Light on Interaction Between Neurological Symptoms and Psychiatric Episodes in Multiple Sclerosis: Novel Hypothesis and Therapeutic Avenues
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 907
Shedding Light on Interaction Between Neurological Symptoms and Psychiatric Episodes in Multiple Sclerosis: Novel Hypothesis and Therapeutic Avenues
- Open Access
- 1 January 2026
- Published by SCIE Publishing Limited in Food Research and Supplementation
- Vol. 1 (2) , 10006
Beneficial Effects of Food Containing Lactononadecapeptide on Memory Function in Elderly Japanese Subjects—A Randomized, Double-Blind, Placebo-Controlled Study
SCIEPublish is an international open-access journal publishing service provider run by SCIE Publishing Limited, dedicated to supporting and inspiring scientists or institutions/societies who aspire to publish high-quality journals.
- 1 January 2026
- Published by SCIE Publishing Limited in Food Research and Supplementation
- Vol. 1 (2) , 10006
Open AccessBeneficial Effects of Food Containing Lactononadecapeptide on Memory Function in Elderly Japanese Subjects—A Randomized, Double-Blind, Placebo-Controlled Study
SCIEPublish is an international open-access journal publishing service provider run by SCIE Publishing Limited, dedicated to supporting and inspiring scientists or institutions/societies who aspire to publish high-quality journals.
- Open Access
- 5 December 2025
- Published by MDPI AG in Preprints.org
Off-Target Effects of Mirabegron on Muscarinic Receptors
Older adults with multiple diseases are likely to be prescribed multiple medications including anticholinergic agents, which are frequently prescribed to manage conditions such as overactive bladder and chronic obstructive pulmonary disease and Parkinson’s disease. Overactive bladder (OAB) has been the subject of increased disease awareness and is a common and significant cause of reduced quality of life, particularly in the elderly. The selective β3 adrenoceptor agonist, mirabegron was developed for the pharmacological treatment of OAB. Mirabegron has been shown to exert off-target effects on various functional proteins such as muscarinic receptors in rat tissues. This agent may relax the detrusor muscle by activating β3 adrenoceptors and also antagonizing muscarinic receptors. Mirabegron and antimuscarinics exerted additive effects on muscarinic receptor binding and relaxant responses of cholinergic contractions of the detrusor muscle. Mirabegron excreted in human urine appears to directly attenuate muscarinic receptor-mediated functions in the bladder. Combination therapy of mirabegron and solifenacin in patients with OAB may enhance not only their therapeutic effects on OAB, but also increase the risk of anticholinergic adverse effects. Therefore, the safety of concomitant use of mirabegron and other drugs such as antimuscarinics for elderly patients needs to be carefully considered.
- 5 December 2025
- Published by MDPI AG in Preprints.org
Open AccessOff-Target Effects of Mirabegron on Muscarinic Receptors
Older adults with multiple diseases are likely to be prescribed multiple medications including anticholinergic agents, which are frequently prescribed to manage conditions such as overactive bladder and chronic obstructive pulmonary disease and Parkinson’s disease. Overactive bladder (OAB) has been the subject of increased disease awareness and is a common and significant cause of reduced quality of life, particularly in the elderly. The selective β3 adrenoceptor agonist, mirabegron was developed for the pharmacological treatment of OAB. Mirabegron has been shown to exert off-target effects on various functional proteins such as muscarinic receptors in rat tissues. This agent may relax the detrusor muscle by activating β3 adrenoceptors and also antagonizing muscarinic receptors. Mirabegron and antimuscarinics exerted additive effects on muscarinic receptor binding and relaxant responses of cholinergic contractions of the detrusor muscle. Mirabegron excreted in human urine appears to directly attenuate muscarinic receptor-mediated functions in the bladder. Combination therapy of mirabegron and solifenacin in patients with OAB may enhance not only their therapeutic effects on OAB, but also increase the risk of anticholinergic adverse effects. Therefore, the safety of concomitant use of mirabegron and other drugs such as antimuscarinics for elderly patients needs to be carefully considered.
- Open Access
- 3 December 2025
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (1)
Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale
The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy. One year has passed since the “Japanese Anticholinergic Risk Scale” was published by the Japanese Society of Geriatric Pharmacy, and the anticholinergic effects of various medications have garnered attention. These medications are used in clinical practice and research. The anticholinergic effects of drugs are not necessarily induced solely by binding to muscarinic receptors and exerting antagonistic actions but may also occur as a result of various combined effects. In this review, we focus on drugs that show differences between the “Yamada Classification,” which was created based on in vitro muscarinic receptor binding activity, and the “Japanese Anticholinergic Risk Scale.” We re‐examine anticholinergic effects and, through a review of the literature, identify drugs that induce “anticholinergic‐like effects” beyond direct muscarinic receptor antagonism. By understanding the potential mechanisms underlying “anticholinergic‐like effects” in drugs where anticholinergic effects listed in the risk scale are not anticipated, we aim to reemphasize the prevalence of drugs with anticholinergic‐like effects.
- 3 December 2025
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (1)
Open AccessFurther Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale
The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy. One year has passed since the “Japanese Anticholinergic Risk Scale” was published by the Japanese Society of Geriatric Pharmacy, and the anticholinergic effects of various medications have garnered attention. These medications are used in clinical practice and research. The anticholinergic effects of drugs are not necessarily induced solely by binding to muscarinic receptors and exerting antagonistic actions but may also occur as a result of various combined effects. In this review, we focus on drugs that show differences between the “Yamada Classification,” which was created based on in vitro muscarinic receptor binding activity, and the “Japanese Anticholinergic Risk Scale.” We re‐examine anticholinergic effects and, through a review of the literature, identify drugs that induce “anticholinergic‐like effects” beyond direct muscarinic receptor antagonism. By understanding the potential mechanisms underlying “anticholinergic‐like effects” in drugs where anticholinergic effects listed in the risk scale are not anticipated, we aim to reemphasize the prevalence of drugs with anticholinergic‐like effects.
- Open Access
Matcha Green Tea Improves Cafeteria-Diet-Induced NAFLD by Modulating the Gut Microbiota in Rats
Background: The aim of this study was to investigate the effects of matcha on lipid metabolism, insulin resistance (IR), inflammation, and gut dysbiosis in non-alcoholic fatty liver disease (NAFLD) induced by a cafeteria diet. Methods: Forty-eight 7-week-old male Wistar rats were divided into six groups (n = 8), including a control group (C), C + 0.2% matcha group (C + 0.2%), C + 1% matcha group (C + 1%), cafeteria group (Caf), Caf + 0.2% matcha group (Caf + 0.2%), and Caf + 1% matcha group (Caf + 1%). All rats were sacrificed at the end of the 12th week of the experiment. A one-way analysis of variance (ANOVA), followed by a Fisher’s post hoc test, was used to determine the significant differences among each of the groups. Results: The results indicated that plasma experiment triglycerides (TGs) significantly increased in the Caf group compared to the C group, and significantly decreased TG levels were found in the Caf + 1% group compared to the Caf group. In addition, the liver total cholesterol and TG had significantly increased in the Caf group, while the 0.2% Matcha intervention can mitigate hepatic lipid accumulation. Blood sugar, serum insulin, the homeostasis model assessment of IR (HOMA-IR), and plasma leptin significantly increased in the Caf group and were significantly lower in the Caf + 0.2% and Caf + 1% groups. Hepatic cytokines significantly increased in the Caf group, while, on the other hand, significantly lower concentrations were found in the Caf + 1% group. In addition, beneficial bacteria including Akkermansia, Faecalibacterium, and Parabacteroides increased after matcha supplementation. Conclusions: These results suggested that 12 weeks of a cafeteria diet can induce abnormal lipid metabolism, IR, liver inflammation, and an altered gut microbiotic composition, while both the 0.2% and 1% matcha interventions might regulate obesity, lipid accumulation, IR, and inflammatory responses, and help maintain a healthier gut microbiota, which may then ameliorate the development of NAFLD.
Open AccessMatcha Green Tea Improves Cafeteria-Diet-Induced NAFLD by Modulating the Gut Microbiota in Rats
Background: The aim of this study was to investigate the effects of matcha on lipid metabolism, insulin resistance (IR), inflammation, and gut dysbiosis in non-alcoholic fatty liver disease (NAFLD) induced by a cafeteria diet. Methods: Forty-eight 7-week-old male Wistar rats were divided into six groups (n = 8), including a control group (C), C + 0.2% matcha group (C + 0.2%), C + 1% matcha group (C + 1%), cafeteria group (Caf), Caf + 0.2% matcha group (Caf + 0.2%), and Caf + 1% matcha group (Caf + 1%). All rats were sacrificed at the end of the 12th week of the experiment. A one-way analysis of variance (ANOVA), followed by a Fisher’s post hoc test, was used to determine the significant differences among each of the groups. Results: The results indicated that plasma experiment triglycerides (TGs) significantly increased in the Caf group compared to the C group, and significantly decreased TG levels were found in the Caf + 1% group compared to the Caf group. In addition, the liver total cholesterol and TG had significantly increased in the Caf group, while the 0.2% Matcha intervention can mitigate hepatic lipid accumulation. Blood sugar, serum insulin, the homeostasis model assessment of IR (HOMA-IR), and plasma leptin significantly increased in the Caf group and were significantly lower in the Caf + 0.2% and Caf + 1% groups. Hepatic cytokines significantly increased in the Caf group, while, on the other hand, significantly lower concentrations were found in the Caf + 1% group. In addition, beneficial bacteria including Akkermansia, Faecalibacterium, and Parabacteroides increased after matcha supplementation. Conclusions: These results suggested that 12 weeks of a cafeteria diet can induce abnormal lipid metabolism, IR, liver inflammation, and an altered gut microbiotic composition, while both the 0.2% and 1% matcha interventions might regulate obesity, lipid accumulation, IR, and inflammatory responses, and help maintain a healthier gut microbiota, which may then ameliorate the development of NAFLD.
- Open Access
- 27 May 2025
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 158 (4) , 363-367
Additive effects of mirabegron on muscarinic receptor binding and on relaxation of cholinergic detrusor muscle contraction by antimuscarinics
- 27 May 2025
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 158 (4) , 363-367
Open AccessAdditive effects of mirabegron on muscarinic receptor binding and on relaxation of cholinergic detrusor muscle contraction by antimuscarinics
- Open Access
Beneficial Effects of Enoki Mushroom Extract on Male Menopausal Symptoms in Japanese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study
With the increase in average life expectancy, age-related male menopause has become a cause of decreased quality of life in men. The present study investigated the efficacy and safety of powdered enoki mushroom extract containing adenosine (test food) for menopausal symptoms in middle-aged and elderly men based on an evaluation of Heinemann’s Aging Males’ Symptoms (AMS) scores. The test food and placebo were administered to healthy men with AMS scores of 27–49 for 12 weeks. AMS score (primary endpoint) and testosterone level (secondary endpoint) were evaluated before and 12 weeks after the intake of the test food and placebo. The intake of the test food for 12 weeks significantly improved the sexual subscale of the AMS. In the cumulative χ2 test, the number of subjects showing high improvement was significantly higher in the test food group than in the placebo food group. In a stratified analysis of subjects divided into two groups based on a change in total testosterone levels of <0.5 ng/mL and ≥0.5 ng/mL after the intake of the test food, the number of subjects with increased total testosterone levels of ≥0.5 ng/mL was significantly higher in the test food group than in the placebo group. These results suggest the beneficial effects of enoki mushroom extract on symptoms of male menopause.
Open AccessBeneficial Effects of Enoki Mushroom Extract on Male Menopausal Symptoms in Japanese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study
With the increase in average life expectancy, age-related male menopause has become a cause of decreased quality of life in men. The present study investigated the efficacy and safety of powdered enoki mushroom extract containing adenosine (test food) for menopausal symptoms in middle-aged and elderly men based on an evaluation of Heinemann’s Aging Males’ Symptoms (AMS) scores. The test food and placebo were administered to healthy men with AMS scores of 27–49 for 12 weeks. AMS score (primary endpoint) and testosterone level (secondary endpoint) were evaluated before and 12 weeks after the intake of the test food and placebo. The intake of the test food for 12 weeks significantly improved the sexual subscale of the AMS. In the cumulative χ2 test, the number of subjects showing high improvement was significantly higher in the test food group than in the placebo food group. In a stratified analysis of subjects divided into two groups based on a change in total testosterone levels of <0.5 ng/mL and ≥0.5 ng/mL after the intake of the test food, the number of subjects with increased total testosterone levels of ≥0.5 ng/mL was significantly higher in the test food group than in the placebo group. These results suggest the beneficial effects of enoki mushroom extract on symptoms of male menopause.
- Open Access
- 5 December 2024
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 25 (1) , 5-13
Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article
Background: Anticholinergic burden, reflecting the cumulative impact of medications with anticholinergic properties, significantly predicts adverse drug reactions and geriatric syndromes in older adults. Although anticholinergic risk scales (ARS) have been developed and validated in various countries, none have been tailored specifically for Japan. The Japanese Anticholinergic Risk Scale (JARS) was developed to adapt the existing ARS frameworks to the Japanese context, considering unique medication profiles and cultural factors.Process: First, a systematic review was performed to follow the protocol registered in PROSPERO (CRD42017076510). A PubMed search from October 2017 to March 2023 was conducted to identify ARS publications post‐September 2017. Based on two algorithms, average scores from the existing scores were used to develop JARS. The Delphi method, an expert consensus approach, was applied to determine the scores for medications that were not established by the algorithms. Sixteen articles identified in our systematic review contributed to JARS development. JARS categorizes 158 medications into three potency groups: 37 drugs scored as 3 (strong), 27 as 2 (moderate), and 94 as 1 (weak).Conclusion: JARS, the newly developed ARS, could be a critical tool for anticholinergic burden assessment in older Japanese populations. Developed through a systematic review and Delphi‐based expert consensus, it encompasses 158 medications, offering a comprehensive anticholinergic burden assessment. Future studies and updates should be conducted to improve the accuracy and clinical applicability of this scale. Geriatr Gerontol Int 2025; 25: 5–13.
- 5 December 2024
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 25 (1) , 5-13
Open AccessDevelopment of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article
Background: Anticholinergic burden, reflecting the cumulative impact of medications with anticholinergic properties, significantly predicts adverse drug reactions and geriatric syndromes in older adults. Although anticholinergic risk scales (ARS) have been developed and validated in various countries, none have been tailored specifically for Japan. The Japanese Anticholinergic Risk Scale (JARS) was developed to adapt the existing ARS frameworks to the Japanese context, considering unique medication profiles and cultural factors.Process: First, a systematic review was performed to follow the protocol registered in PROSPERO (CRD42017076510). A PubMed search from October 2017 to March 2023 was conducted to identify ARS publications post‐September 2017. Based on two algorithms, average scores from the existing scores were used to develop JARS. The Delphi method, an expert consensus approach, was applied to determine the scores for medications that were not established by the algorithms. Sixteen articles identified in our systematic review contributed to JARS development. JARS categorizes 158 medications into three potency groups: 37 drugs scored as 3 (strong), 27 as 2 (moderate), and 94 as 1 (weak).Conclusion: JARS, the newly developed ARS, could be a critical tool for anticholinergic burden assessment in older Japanese populations. Developed through a systematic review and Delphi‐based expert consensus, it encompasses 158 medications, offering a comprehensive anticholinergic burden assessment. Future studies and updates should be conducted to improve the accuracy and clinical applicability of this scale. Geriatr Gerontol Int 2025; 25: 5–13.
- Open Access
- 1 October 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (10) , 1246
Identification of Sinapic Acid Derivatives from Petit Vert Leaves and Their Effects on Glucose Uptake in C2C12 Murine Myoblasts
Petit vert (scientific name: Brassica oleracea var. gemmifera DC. × Brassica oleracea var. acephala DC.) is a new variety of vegetable created by crossbreeding kale and brussel sprouts (Brassica oleracea species). The present study aimed to identify biologically active compounds in extracts of the outer leaves of Petit vert by purification and to examine their biological activities. The dried and powdered outer leaves of Petit vert were extracted, fractionated, and purified to isolate active compounds. Mass spectrometry (MS) was used to identify the compounds, and nuclear magnetic resonance (NMR) spectroscopy was performed to elucidate their structures. The compounds isolated from Petit vert leaves were glycosides that contained kaempferol, quercetin (flavonol), or sinapic acid (phenylpropanoid). Glucose uptake in cultured C2C12 murine myoblasts in the absence of insulin was significantly increased by these compounds, kaempferol, sinapic acid, and ferulic acid, while uptake in the presence of insulin was also significantly increased by compounds 3 and 4, kaempferol, and sinapic acid. The effect was not necessarily concentration-dependent, and some agents decreased the glucose uptake at higher concentrations. The present study reports for the first time the isolation of five compounds containing sinapic acid from the outer leaves of Petit vert and their stimulation of glucose uptake in cultured C2C12 murine myoblasts. The results obtained herein suggest the potential of these compounds to effectively attenuate hyperglycemia and maintain muscle strength by promoting glucose metabolism in muscle cells.
- 1 October 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (10) , 1246
Open AccessIdentification of Sinapic Acid Derivatives from Petit Vert Leaves and Their Effects on Glucose Uptake in C2C12 Murine Myoblasts
Petit vert (scientific name: Brassica oleracea var. gemmifera DC. × Brassica oleracea var. acephala DC.) is a new variety of vegetable created by crossbreeding kale and brussel sprouts (Brassica oleracea species). The present study aimed to identify biologically active compounds in extracts of the outer leaves of Petit vert by purification and to examine their biological activities. The dried and powdered outer leaves of Petit vert were extracted, fractionated, and purified to isolate active compounds. Mass spectrometry (MS) was used to identify the compounds, and nuclear magnetic resonance (NMR) spectroscopy was performed to elucidate their structures. The compounds isolated from Petit vert leaves were glycosides that contained kaempferol, quercetin (flavonol), or sinapic acid (phenylpropanoid). Glucose uptake in cultured C2C12 murine myoblasts in the absence of insulin was significantly increased by these compounds, kaempferol, sinapic acid, and ferulic acid, while uptake in the presence of insulin was also significantly increased by compounds 3 and 4, kaempferol, and sinapic acid. The effect was not necessarily concentration-dependent, and some agents decreased the glucose uptake at higher concentrations. The present study reports for the first time the isolation of five compounds containing sinapic acid from the outer leaves of Petit vert and their stimulation of glucose uptake in cultured C2C12 murine myoblasts. The results obtained herein suggest the potential of these compounds to effectively attenuate hyperglycemia and maintain muscle strength by promoting glucose metabolism in muscle cells.